• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环miRNA-21作为急性心肌梗死的早期潜在诊断生物标志物：一项荟萃分析。

Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.

作者信息

Wang Ke, Li Kai, Li Zhuoyuan, Yan Xizhang

机构信息

Department of Clinical Medicine, Xi'an Medical University, Xi'an, Shannxi, China.

Department of the Project of Prevention and Treatment of Respiratory Diseases, Xi'an Medical University, Xi'an, Shannxi, China.

出版信息

Front Cardiovasc Med. 2024 Aug 22;11:1330884. doi: 10.3389/fcvm.2024.1330884. eCollection 2024.

DOI:10.3389/fcvm.2024.1330884
PMID:39238499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11374624/
Abstract

INTRODUCTION

There exists a knowledge gap concerning the clinical significance of miRNA-21; therefore, in the present study, we aimed to estimate the diagnostic and prognostic accuracy and sensitivity of miRNA-21 in acute myocardial infarction (AMI) by performing an evidence-based meta-analysis of previous AMI-related clinical studies.

METHODS

Chinese and English literature published before April 2024 were searched, and data were reviewed and extracted. After quality appraisal, the STATA 16.0 software was used for the effect size analysis of the various treatments described in the literature.

RESULTS

A total of 14 valid documents were retrieved from 562 studies. The results of the systematic review revealed that for the patients with AMI vs. those without non-AMI, the aggregated odds ratio reached 5.37 (95% confidence interval 3.70-7.04). The general sensitivity and specificity for the circulating miRNA-21 levels in diagnosing AMI were 0.83 and 0.81, respectively.

DISCUSSION

Thus, the meta-analysis of 14 AMI-related clinical trials highlighted that miRNA-21 may serve as a promising biomarker for diagnosing AMI.

摘要

引言

关于miRNA - 21的临床意义存在知识空白；因此，在本研究中，我们旨在通过对先前与急性心肌梗死（AMI）相关的临床研究进行循证荟萃分析，评估miRNA - 21在急性心肌梗死中的诊断和预后准确性及敏感性。

方法

检索了2024年4月之前发表的中英文文献，并对数据进行了审查和提取。经过质量评估后，使用STATA 16.0软件对文献中描述的各种治疗方法进行效应量分析。

结果

从562项研究中总共检索到14篇有效文献。系统评价结果显示，与非AMI患者相比，AMI患者的汇总比值比达到5.37（95%置信区间3.70 - 7.04）。循环miRNA - 21水平诊断AMI的总体敏感性和特异性分别为0.83和0.81。

讨论

因此，对14项与AMI相关的临床试验进行的荟萃分析强调，miRNA - 21可能是诊断AMI的一个有前景的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/4a7420ecd6cb/fcvm-11-1330884-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/3b569eb51a85/fcvm-11-1330884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/1be5f0c45f4c/fcvm-11-1330884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/558ea819534f/fcvm-11-1330884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/8a494a49c6af/fcvm-11-1330884-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/5efae7d0e644/fcvm-11-1330884-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/1170e7de6cf0/fcvm-11-1330884-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/9bb4fef86206/fcvm-11-1330884-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/758b4f364c86/fcvm-11-1330884-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/2deb5dcf0781/fcvm-11-1330884-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/4a7420ecd6cb/fcvm-11-1330884-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/3b569eb51a85/fcvm-11-1330884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/1be5f0c45f4c/fcvm-11-1330884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/558ea819534f/fcvm-11-1330884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/8a494a49c6af/fcvm-11-1330884-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/5efae7d0e644/fcvm-11-1330884-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/1170e7de6cf0/fcvm-11-1330884-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/9bb4fef86206/fcvm-11-1330884-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/758b4f364c86/fcvm-11-1330884-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/2deb5dcf0781/fcvm-11-1330884-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/224a/11374624/4a7420ecd6cb/fcvm-11-1330884-g010.jpg

相似文献

1
Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.循环miRNA-21作为急性心肌梗死的早期潜在诊断生物标志物：一项荟萃分析。
Front Cardiovasc Med. 2024 Aug 22;11:1330884. doi: 10.3389/fcvm.2024.1330884. eCollection 2024.
2
Circulating microRNA-208 family as early diagnostic biomarkers for acute myocardial infarction: A meta-analysis.循环 microRNA-208 家族作为急性心肌梗死的早期诊断生物标志物：一项荟萃分析。
Medicine (Baltimore). 2021 Dec 23;100(51):e27779. doi: 10.1097/MD.0000000000027779.
3
Value of Blood-Based microRNAs in the Diagnosis of Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.基于血液的微小RNA在急性心肌梗死诊断中的价值：一项系统评价和荟萃分析
Front Physiol. 2020 Aug 14;11:691. doi: 10.3389/fphys.2020.00691. eCollection 2020.
4
Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction.与动脉粥样硬化相关的循环微小RNA作为急性心肌梗死的新型敏感预测指标。
PLoS One. 2014 Sep 3;9(9):e105734. doi: 10.1371/journal.pone.0105734. eCollection 2014.
5
Identification of microRNAs as diagnostic biomarkers for acute myocardial infarction in Asian populations: A systematic review and meta-analysis.鉴定微小RNA作为亚洲人群急性心肌梗死的诊断生物标志物：一项系统评价和荟萃分析。
Medicine (Baltimore). 2017 Jun;96(24):e7173. doi: 10.1097/MD.0000000000007173.
6
Circulating miRNA-21 as a diagnostic biomarker for acute coronary syndrome: a systematic review and meta-analysis of diagnostic test accuracy study.循环miRNA-21作为急性冠状动脉综合征的诊断生物标志物：诊断试验准确性研究的系统评价和荟萃分析
Cardiovasc Diagn Ther. 2024 Jun 30;14(3):328-339. doi: 10.21037/cdt-23-385. Epub 2024 Jun 11.
7
Exploring diagnostic and prognostic predictive values of microRNAs for acute myocardial infarction: A PRISMA-compliant systematic review and meta-analysis.探讨 microRNAs 对急性心肌梗死的诊断和预后预测价值：一项符合 PRISMA 原则的系统评价和荟萃分析。
Medicine (Baltimore). 2021 Jul 23;100(29):e26627. doi: 10.1097/MD.0000000000026627.
8
Prognostic value of circulating microRNA-21-5p and microRNA-126 in patients with acute myocardial infarction and infarct-related artery total occlusion.循环微小RNA-21-5p和微小RNA-126在急性心肌梗死及梗死相关动脉完全闭塞患者中的预后价值
Front Cardiovasc Med. 2022 Oct 18;9:947721. doi: 10.3389/fcvm.2022.947721. eCollection 2022.
9
Circulating MicroRNA-499 as a Diagnostic Biomarker for Acute Myocardial Infarction: A Meta-analysis.循环 microRNA-499 作为急性心肌梗死的诊断生物标志物：一项荟萃分析。
Dis Markers. 2019 May 2;2019:6121696. doi: 10.1155/2019/6121696. eCollection 2019.
10
Diagnostic and prognostic value of miR-486-5p, miR-451a, miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction.miR-486-5p、miR-451a、miR-21-5p 和单核细胞/高密度脂蛋白胆固醇比值在急性心肌梗死患者中的诊断和预后价值。
Heart Vessels. 2023 Mar;38(3):318-331. doi: 10.1007/s00380-022-02172-2. Epub 2022 Oct 10.

本文引用的文献

1
Prognostic value of circulating microRNA-21-5p and microRNA-126 in patients with acute myocardial infarction and infarct-related artery total occlusion.循环微小RNA-21-5p和微小RNA-126在急性心肌梗死及梗死相关动脉完全闭塞患者中的预后价值
Front Cardiovasc Med. 2022 Oct 18;9:947721. doi: 10.3389/fcvm.2022.947721. eCollection 2022.
2
Diagnostic and prognostic value of miR-486-5p, miR-451a, miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction.miR-486-5p、miR-451a、miR-21-5p 和单核细胞/高密度脂蛋白胆固醇比值在急性心肌梗死患者中的诊断和预后价值。
Heart Vessels. 2023 Mar;38(3):318-331. doi: 10.1007/s00380-022-02172-2. Epub 2022 Oct 10.
3
Dynamic Changes in miR-21 Regulate Right Ventricular Dysfunction in Congenital Heart Disease-Related Pulmonary Arterial Hypertension.
miR-21 的动态变化调节先天性心脏病相关肺动脉高压的右心功能障碍。
Cells. 2022 Feb 6;11(3):564. doi: 10.3390/cells11030564.
4
Therapeutic Value of miRNAs in Coronary Artery Disease.miRNAs 在冠状动脉疾病中的治疗价值。
Oxid Med Cell Longev. 2021 Apr 12;2021:8853748. doi: 10.1155/2021/8853748. eCollection 2021.
5
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
6
The Cell Type-Specific Functions of miR-21 in Cardiovascular Diseases.微小RNA-21在心血管疾病中的细胞类型特异性功能
Front Genet. 2020 Nov 20;11:563166. doi: 10.3389/fgene.2020.563166. eCollection 2020.
7
Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.预防射血分数保留型心力衰竭（HFpEF）：在寡核苷酸治疗时代重新审视 microRNA-21 抑制。
Cardiovasc Pathol. 2020 Nov-Dec;49:107243. doi: 10.1016/j.carpath.2020.107243. Epub 2020 May 19.
8
Diagnostic Role of Plasma MicroRNA-21 in Stable and Unstable Angina Patients and Association with Aging.血浆微小RNA-21在稳定型和不稳定型心绞痛患者中的诊断作用及其与衰老的关系
Cardiol Res Pract. 2020 Apr 13;2020:9093151. doi: 10.1155/2020/9093151. eCollection 2020.
9
Initial Invasive or Conservative Strategy for Stable Coronary Disease.稳定型冠心病的初始侵入性或保守治疗策略。
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
10
Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis.急性心肌梗死患者血清和血浆中微小RNA表达的差异：一项系统的配对比较分析。
Sci Rep. 2020 Mar 25;10(1):5373. doi: 10.1038/s41598-020-61507-z.